Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

L.A. McKeown

June 07, 2023

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content